MIV Therapeutics to Highlight Latest HAp Advancements at Leading International Scientific Conference on Biomaterials; MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has been accepted to present some of its latest technology achievements at the annual international meeting of the Society of Biomaterials in Pittsburgh, Pennsylvania, in April.

MIV Therapeutics is a leader in the research and development of a novel organic material, called Hydroxyapatite (HAp), which is designed to provide medically needed advantages over the current generation of polymer coatings and materials used in the growing, multibillion-dollar worldwide marketplace for vascular stents and other medical products. At the conference, to be held April 26 - 27, 2006, two Company presentations will be delivered.

In the first, Dr. Quanzu Yang, a scientist at the University of British Columbia who works under supervision of Dr. Tom Troczynski, Vice President of Coatings at MIVT and Professor of Ceramics at UBC, will present a poster entitled, "Biopolymer-Hydroxyapatite Matrix Composite Coatings for Stents," which highlights some of the latest HAp composite coating achievements.

"This next-generation family of composite coatings essentially combines the most desirable properties of bioceramics with those of biopolymers to create greater durability, strength and elasticity," said Dr. Troczynski. "Presented composite would be particularly suitable for coating vascular stents and other devices that are often exposed to significant stresses or possible deformation during implantation or other surgical procedures."

At the same venue Arc Rajtar, MIVT's Chief Technology Officer, will present a poster entitled, "Progress in Processing and Evaluation of Hydroxyapatite Ultra-Thin Film Coatings for Coronary Stents." Mr. Rajtar will report on advancements in the processing of a new ultra-thin film (less than 0.5 micrometer) HAp coating and highlight the successful results of a series of recent porcine tests, in which pigs were implanted with ultra-thin HAp coatings in both biologically inert or "passive" form and also an advanced drug-eluting form.

"MIVT have been exploring the extraordinary potential of HAp for the last several years and among its achievements has developed an ultra-thin coating for coronary stents that could provide crucial medical advantages," said Mr. Rajtar. "In a recently completed series of porcine tests, these advantages were further reinforced, as the test data demonstrate that the coatings not only have excellent biocompatibility, but are also non-toxic, and do not induce allergic or inflammatory reactions."

Under the terms of a Collaborative Research Agreement with the University of British Columbia, MIV Therapeutics' research and development team works closely with UBC's Department of Materials Engineering to develop innovative HAp technologies for use with implantable vascular stents and novel drug delivery and drug-elution systems.

"This meeting comes at an exciting time, as we progress closer toward the commercialization phase of our HAp technologies, and we are very pleased to have this opportunity to present some of our advancements to this discerning audience of world-class specialists in the field," said Alan Lindsay, CEO of MIV Therapeutics. "The international conference of the Society of Biomaterials annually showcases some of the leading cutting-edge technologies from around the world, and it is a privilege for MIV Therapeutics to participate with two posters at this meeting."

About the (U.S.) Society for Biomaterials Conference

The U.S.-based Society for Biomaterials is a professional society which promotes advances in all phases of materials research and development by encouragement of cooperative educational programs, clinical applications, and professional standards in the biomaterials field. Attendees of the annual Society for Biomaterials meeting reflect the multidisciplinary nature of this field, and work every day to advance these topic areas by applying many of the lessons learned at the SFB Meeting to new clinical approaches. For more information on the upcoming conference, please visit www.biomaterials.org/Meetings/06AnnualMeeting/index.htm

About the University of British Columbia

The University of British Columbia (UBC), located in the Pacific Rim gateway of Vancouver, Canada, ranks in the top 10 of North American universities in technology licensing and commercialization, and generates more U.S. patent applications than any other Canadian public institution. The UBCeram Group at the UBC specializes in a number of aspects of ceramics research, and focuses on bioceramics for coatings and bulk applications.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.